Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2008-07-15
2008-07-15
Helms, Larry R. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387300, C530S388100, C530S388800, C530S391100, C424S133100, C424S141100, C424S155100, C424S174100, C435S007100
Reexamination Certificate
active
07399835
ABSTRACT:
The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.
REFERENCES:
patent: 4433059 (1984-02-01), Chang et al.
patent: 4861581 (1989-08-01), Epstein et al.
patent: 5171665 (1992-12-01), Hellstrom et al.
patent: 5484596 (1996-01-01), Hanna, Jr. et al.
patent: 5693763 (1997-12-01), Codington et al.
patent: 5750102 (1998-05-01), Eisenbach et al.
patent: 5780033 (1998-07-01), Torchilin et al.
patent: 5783186 (1998-07-01), Arakawa et al.
patent: 5849876 (1998-12-01), Linsley et al.
patent: 5869045 (1999-02-01), Hellstrom et al.
patent: 5869268 (1999-02-01), Kudo et al.
patent: 7189825 (2007-03-01), Young et al.
patent: 2003/0138425 (2003-07-01), Mather
patent: 2006/0140963 (2006-06-01), Young et al.
patent: WO03/048302 (2003-06-01), None
patent: WO03/086456 (2003-10-01), None
T. Nishihara et al, “Antibody-dependent cytotoxicity mediated by chimeric monoclonal antibody Nd2 and experimental immunotherapy for pancreatic cancer”, Jpn. J. Cancer Res., 91:817-824 (Aug. 2000).
S. Green et al, “Disruption of cell-cell adhesion enhances antibody-dependent cellular cytotoxicity: implications for antibody-based therapeutics of cancer”, Cancer Research, 62:6891-6900 (Dec. 2002).
D. Buchsbaum et al, et al, “Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model”, Clinical Cancer Research, 9:3731-3741 (Sep. 2003).
Carroll et al., “Monoclonal Antibodies to Tissue-Specific Cell Surface Antigens”, Clinical Immunology and Immunopathology (1984), vol. 33, pp. 268-281.
Jarvis et al., “Expression and Function of the Complement Membrane Attack Complex Inhibitor Protein (CD59) in Human Prostate Cancer”, Int. J. Cancer (1997), vol 71, pp. 1049-1055.
O'Donnell et al., “Efficacy and Toxicity of Radioimmunotherapy With 90Y-DOTA-Peptide-ChL6 for PC3-Tumored Mice”, The Prostate (2000), vol. 44, pp. 187-192.
Ware et al., “Production of Monoclonal Antibody alpha Pro3 Recognizing a Human Prostatic Carcinoma Antigen”, Cancer Research (1982), vol. 42, pp. 1215-1222.
Cechetto Lisa M.
Hahn Susan E.
Young David S. F.
Arius Research Inc.
Gussow Anne M.
Helms Larry R.
McHale & Slavin P.A.
LandOfFree
Cancerous disease modifying antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cancerous disease modifying antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cancerous disease modifying antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2779450